» Articles » PMID: 37493998

Small Molecule Heat Shock Protein 27 Inhibitor J2 Decreases Ovarian Cancer Cell Proliferation Via Induction of Apoptotic Pathways

Overview
Journal Med Oncol
Publisher Springer
Specialty Oncology
Date 2023 Jul 26
PMID 37493998
Authors
Affiliations
Soon will be listed here.
Abstract

Heat shock protein 27 (Hsp27) is an important member of the chaperone protein family and its overexpression promotes cancer cell survival. Here, we investigated the apoptosis inducer role of the J2 compound (Hsp27 inhibitor) in human ovarian cancer cell lines (SKOV3 and OVCAR-3). Cell proliferation was measured by MTT assay. The parameters of J2-Hsp27 interaction were determined with molecular docking calculation. The inhibitory effect of the J2 compound on Hsp27 chaperone activity was investigated by luciferase activity assay. Finally, the apoptotic inducer role of the J2 compound on SKOV3 and OVCAR-3 cells was determined by RT-PCR and caspase-3 activity assay. J2 compound decreased SKOV3 and OVCAR-3 cell proliferation in a dose-dependent manner at 48 h with IC values of 17.34 µM and 12.63 µM, respectively. J2 inhibited the refolding process of denatured luciferase as an Hsp27 inhibitor. Molecular docking calculation was carried out to determine the interaction between Hsp27 and J2. The results indicated that J2 selectively binds to the phosphorylation site of the Hsp27 and inhibits the phosphorylation process of Hsp27. To determine the apoptotic potential of the J2 compound against ovarian cancer cells, the mRNA expression levels of apoptotic and antiapoptotic markers (Bax, Bcl-2, Bcl-xL, Cyt-c, p53, Apaf-1, Cas-3, Cas-8, Cas-9, TNF-α, DAXX, and Ask-1) were measured using RT-PCR. While J2 increased the expressions of apoptotic genes, it decreased the expressions of anti-apoptotic genes. Further, the J2 compound increased Cas-3 activity in SKOV3 and OVCAR-3 at 5.52 and 4.12 folds, respectively. These results confirm that J2 has great potential and significance in the stimulation of apoptosis in ovarian cancer cells as an Hsp27 inhibitor.

Citing Articles

HSP27/IL-6 axis promotes OSCC chemoresistance, invasion and migration by orchestrating macrophages via a positive feedback loop.

Qi Y, Cao J, Jiang M, Lin Y, Li W, Li B Cell Biol Toxicol. 2025; 41(1):36.

PMID: 39873845 PMC: 11775009. DOI: 10.1007/s10565-024-09983-1.


[Effect of phosphorylated HSP27 on the proliferation and metastasis of nasopharyngeal carcinoma and its mechanism].

Bi S, Wu H, Fan H, Wan L, Li G Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2024; 38(11):1017-1023.

PMID: 39534892 PMC: 11879713. DOI: 10.13201/j.issn.2096-7993.2024.11.005.


Heat shock proteins as hallmarks of cancer: insights from molecular mechanisms to therapeutic strategies.

Zuo W, Pang Q, Zhu X, Yang Q, Zhao Q, He G J Hematol Oncol. 2024; 17(1):81.

PMID: 39232809 PMC: 11375894. DOI: 10.1186/s13045-024-01601-1.


Targeting z-Crystallin by aspirin restores the sensitivity to cisplatin in resistant A2780 ovarian cancer cells.

Lulli M, Trabocchi A, Roviello G, Catalano M, Papucci L, Parenti A Front Pharmacol. 2024; 15:1377028.

PMID: 39021835 PMC: 11252033. DOI: 10.3389/fphar.2024.1377028.


Triple Silencing of HSP27, cFLIP, and CLU Genes Promotes the Sensitivity of Doxazosin-Induced Apoptosis in PC-3 Prostate Cancer Cells.

Cho J, Sun S, Im E, Yang H, Yoo T Medicines (Basel). 2024; 11(3).

PMID: 38535120 PMC: 10971947. DOI: 10.3390/medicines11030007.

References
1.
Reid B, Permuth J, Sellers T . Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017; 14(1):9-32. PMC: 5365187. DOI: 10.20892/j.issn.2095-3941.2016.0084. View

2.
Penny S . Ovarian Cancer: An Overview. Radiol Technol. 2020; 91(6):561-575. View

3.
Goff B . Symptoms associated with ovarian cancer. Clin Obstet Gynecol. 2012; 55(1):36-42. DOI: 10.1097/GRF.0b013e3182480523. View

4.
Dilley J, Burnell M, Gentry-Maharaj A, Ryan A, Neophytou C, Apostolidou S . Ovarian cancer symptoms, routes to diagnosis and survival - Population cohort study in the 'no screen' arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Gynecol Oncol. 2020; 158(2):316-322. PMC: 7453382. DOI: 10.1016/j.ygyno.2020.05.002. View

5.
Orr B, Edwards R . Diagnosis and Treatment of Ovarian Cancer. Hematol Oncol Clin North Am. 2018; 32(6):943-964. DOI: 10.1016/j.hoc.2018.07.010. View